Hengrui Medicine (600276.SH): SHR-4610 Injection receives notification of drug clinical trial approval.

Intelligent Financial News APP, Hengrui Medicine (600276.SH) announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., has recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (referred to as the "NMPA") for SHR-4610 injection. The company will soon start clinical trials.